M
Meihua Wang
Researcher at Radiation Therapy Oncology Group
Publications - 36
Citations - 3789
Meihua Wang is an academic researcher from Radiation Therapy Oncology Group. The author has contributed to research in topics: Radiation therapy & Temozolomide. The author has an hindex of 18, co-authored 33 publications receiving 3309 citations. Previous affiliations of Meihua Wang include Merck & Co. & American College of Radiology.
Papers
More filters
Journal ArticleDOI
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross,Meihua Wang,Edward G. Shaw,Robert B. Jenkins,David Brachman,Jan C. Buckner,Karen Fink,Luis Souhami,Normand Laperriere,Walter J. Curran,Minesh P. Mehta +10 more
TL;DR: For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
Journal ArticleDOI
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert,Meihua Wang,Kenneth Aldape,Roger Stupp,Monika E. Hegi,Kurt A. Jaeckle,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Minhee Won,Deborah T. Blumenthal,Anita Mahajan,Christopher J. Schultz,Sara Erridge,Brigitta G. Baumert,Kristen I. Hopkins,Tzahala Tzuk-Shina,Paul D. Brown,Arnab Chakravarti,Walter J. Curran,Minesh P. Mehta +20 more
TL;DR: This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation.
Journal ArticleDOI
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Gregory Cairncross,Meihua Wang,Robert B. Jenkins,Edward G. Shaw,Caterina Giannini,David Brachman,Jan C. Buckner,Karen Fink,Luis Souhami,Normand Laperriere,Jason T. Huse,Minesh P. Mehta,Walter J. Curran +12 more
TL;DR: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT, and although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.
Journal ArticleDOI
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
Edward G. Shaw,Meihua Wang,Stephen W. Coons,David Brachman,Jan C. Buckner,Keith J. Stelzer,Geoffrey R. Barger,Paul D. Brown,Mark R. Gilbert,Minesh P. Mehta +9 more
TL;DR: PFS but not OS was improved for adult patients with LGG receiving RT + PCV versus RT alone, suggesting a delayed benefit for chemotherapy.
Journal ArticleDOI
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320.
Paul W. Sperduto,Meihua Wang,H. Ian Robins,Michael C. Schell,Maria Werner-Wasik,Ritsuko Komaki,Luis Souhami,Mark K. Buyyounouski,Deepak Khuntia,W. Demas,Sunjay Shah,Lucien A. Nedzi,Gad Perry,John H. Suh,Minesh P. Mehta +14 more
TL;DR: The addition of TMZ or ETN to WBRT + SRS in NSCLC patients with 1 to 3 brain metastases did not improve survival and possibly had a deleterious effect, and data suggest but do not prove that increased toxicity was the cause of inferior survival in the drug arms.